Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Slow is good

Nektar data show how its slow release opioid could avoid abuse potential

Nektar Therapeutics now has proof of mechanism for its small molecule polymer conjugates in a new therapeutic area: pain. Last week, the company presented Phase I data showing its novel mu opioid receptor agonist construct is safe and produces the expected delays in analgesia that Nektar hopes could reduce both side effects and the potential for abuse.

Opioid abuse and dependence are thought to be reinforced by the temporal association between a drug's administration and

Read the full 748 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers